MIRA Pharmaceuticals, Inc. (MIRA) Key Metrics
MIRA valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $26.6M
- Enterprise value
- $27.9M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 4.4 10-yr median 4.5
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.49
MIRA key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMIRA valuation Price multiples at each fiscal year-end price.
MIRA returns How much profit the business earns on the capital it uses.
MIRA per-share figures Results divided by the shares outstanding at year-end.
MIRA financial health Debt, liquidity and how easily interest is covered.
MIRA valuation history
MIRA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MIRA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MIRA price vs earnings per share
MIRA key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $35.8M | $17.6M | $19.5M | — | — | — |
| Enterprise value | $29.4M | $14.8M | $14.9M | — | — | — |
| Price / book | 3.4 | 8.0 | 4.5 | — | — | — |
| Earnings yield | −29.2% | −44.6% | −61.5% | — | — | — |
| Free cash flow yield | −13.0% | −31.6% | −23.2% | — | — | — |
| Share price at fiscal year-end | $1.51 | $1.14 | $1.05 | — | — | — |
| Per share | ||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$0.44 | −$0.51 | −$0.65 | −$0.48 | −$0.15 | −$0.00 |
| Operating cash flow per share | −$0.20 | −$0.36 | −$0.24 | −$0.38 | −$0.09 | −$0.00 |
| Free cash flow per share | −$0.20 | −$0.36 | −$0.24 | −$0.38 | −$0.09 | −$0.00 |
| Cash per share | $0.27 | $0.18 | $0.25 | $0.02 | $0.19 | $0.00 |
| Book value per share | $0.44 | $0.14 | $0.24 | −$0.04 | $0.15 | −$0.00 |
| Tangible book value per share | $0.44 | $0.14 | $0.24 | −$0.04 | $0.15 | −$0.00 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | — | — | $0.00 | $0.03 | $0.02 | $0.01 |
| Shares outstanding | 23.7M | 15.4M | 18.6M | 14.7M | 14.7M | 14.7M |
| Change in shares outstanding | +53.4% | −16.8% | +25.9% | 0.0% | 0.0% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −165.9% | −238.9% | −634.3% | — | −198.5% | — |
| Return on invested capital (ROIC) | −486.0% | — | — | — | — | −288.5% |
| Return on assets (ROA) | −149.0% | −199.9% | −413.9% | −335.0% | −128.9% | −303.9% |
| Return on tangible assets | −94.1% | −268.6% | −242.9% | −822.6% | −64.9% | −303.9% |
| Financial health | ||||||
| Total debt | — | — | $5,061 | $491,231 | $293,062 | $90,000 |
| Cash & short-term investments | $6.3M | $2.8M | $4.6M | $350,978 | $2.8M | $3,491 |
| Net debt | −$6.3M | −$2.8M | −$4.6M | $140,253 | −$2.5M | $86,509 |
| Debt / equity | — | — | 0.00 | — | 0.13 | — |
| Debt / assets | — | — | 0.00 | 0.57 | 0.09 | 4.02 |
| Current ratio | 15.75 | 3.99 | 8.70 | 0.36 | 2.66 | 0.04 |
| Quick ratio | 15.75 | 3.99 | 8.73 | 0.36 | 2.66 | 0.04 |
| Interest coverage | — | -48.4 | -2.5 | -687.6 | -88.3 | -185.8 |
| Working capital | $10.4M | $2.2M | $4.3M | −$875,634 | $1.8M | −$86,873 |
| Invested capital | $4.0M | −$633,181 | −$223,159 | −$455,979 | −$255,132 | $18,516 |
| Tangible asset value | $10.4M | $2.2M | $4.4M | −$596,232 | $2.3M | −$67,993 |
| Net current asset value | $10.4M | $2.2M | $4.3M | −$959,901 | $1.8M | −$86,873 |
| Graham net-net per share | $0.24 | $0.14 | $0.22 | −$0.07 | $0.12 | −$0.01 |
| Capital allocation | ||||||
| Capex / depreciation | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||||
| Days of inventory on hand | — | — | -0.5 | — | — | — |
| Days payables outstanding | — | — | 30.9 | — | — | — |
| Receivables turnover | — | — | 0.00 | — | — | — |
| Payables turnover | — | — | 11.81 | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | $11,862 | — | — | — |
| Average payables | $426,276 | $630,956 | $722,059 | $566,980 | $228,406 | — |
| Average inventory | — | — | −$11,862 | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from MIRA's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MIRA valuation and financial ratios
MIRA Pharmaceuticals earned a return on equity of −165.9% and a return on invested capital of −486.0% in fiscal 2025. The share count rose 60.7% from 14.7M to 23.7M over 5 years.
See the MIRA income statement, the MIRA chart for price history, or the MIRA stock overview for the latest quote and news.
MIRA key metrics FAQ
What is MIRA Pharmaceuticals's return on equity?
MIRA Pharmaceuticals's return on equity (ROE) was −165.9% in fiscal 2025: net income of -$10.4 million on average shareholders' equity of $6.3 million.
What is MIRA Pharmaceuticals's ROIC?
MIRA Pharmaceuticals's return on invested capital was −486.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
What is MIRA Pharmaceuticals's free cash flow yield?
MIRA Pharmaceuticals generated -$4.7 million of free cash flow in fiscal 2025, a free cash flow yield of −13.0% on its market value at year-end ($35.8 million).
What is MIRA Pharmaceuticals's current ratio?
MIRA Pharmaceuticals's current ratio was 15.75 at the end of fiscal 2025: current assets were 15.75 times current liabilities.